These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16984751)

  • 1. Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw.
    Yageman LA; Cronin SM; Peres E; Abidi MH; Ibrahim RB
    J Oncol Pharm Pract; 2006 Jun; 12(2):119-21. PubMed ID: 16984751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
    McDonnell AM; Lenz KL
    Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
    Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
    J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
    Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
    Radtke ML; Kolesar JM
    J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.
    Fliedner M; Baguet B; Blankart J; Davies M; Henriques E; Leather A; Mazur E; Mihály K; Peeters L; Radványiné A; Sedlackova B
    Eur J Oncol Nurs; 2007; 11 Suppl 1():S19-26. PubMed ID: 17540295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
    Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S; Nickleach D; Gao J; Lonial S; Waller EK
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
    Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
    Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
    Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
    Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient oral cavity and skin complications after mucositis preventing therapy (palifermin) in a patient after allogeneic PBSCT. Case history.
    Grzegorczyk-Jaźwińska A; Kozak I; Karakulska-Prystupiuk E; Rokicka M; Ganowicz E; Dwilewicz-Trojaczek J; Górska R
    Adv Med Sci; 2006; 51 Suppl 1():66-8. PubMed ID: 17460832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palifermin as treatment in dose-intense conventional polychemotherapy induced mucositis.
    Hueber AJ; Leipe J; Roesler W; Kalden JR; Kallert S; Rech J
    Haematologica; 2006 Aug; 91(8 Suppl):ECR32. PubMed ID: 16923516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.
    Abidi MH; Agarwal R; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Zonder J; Ratanatharathorn V; Uberti J
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1455-61. PubMed ID: 22453252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keratinocyte growth factor.
    Athar U; Gentile TC
    Expert Opin Biol Ther; 2009 Jun; 9(6):779-87. PubMed ID: 19456212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
    Beaven AW; Shea TC
    Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
    Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
    Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma.
    Kobbe G; Bruns I; Schroeder T; Czibere A; Warnecke J; Hieronimus N; Safaian N; Kondakci M; Saure C; Germing U; Haas R; Fenk R
    Ann Oncol; 2010 Sep; 21(9):1898-1904. PubMed ID: 20233744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of osteonecrosis of the jaw in patients with multiple myeloma.
    Badros A; Terpos E; Katodritou E; Goloubeva O; Kastritis E; Verrou E; Zervas K; Baer MR; Meiller T; Dimopoulos MA
    J Clin Oncol; 2008 Dec; 26(36):5904-9. PubMed ID: 19018084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma.
    Montazeri AH; Erskine JG; McQuaker IG
    Eur J Haematol; 2007 Jul; 79(1):69-71. PubMed ID: 17598839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.